b. Specific prerequisites that you believe should be met to foster applicability of 'omics technologies for chemicals risk assessment.
In the following, all responses received are presented (with minor editing from the authors of the present survey). Figures in brackets relate to the respective numberings of the questions listed above. 'omics projects in the pipeline, though: An example is the 'omics study at Concawe that aims at supporting grouping of petroleum streams and read across within such groups (its pilot study, which also includes methodological details, has been published by Grimm et al. (2016) ). This study will, however, not be used directly for
MoA arguments in REACH dossiers or for a specific toxicological endpoint.
(3a) We do not use 'omics data for regulatory purposes, since there is still too much noise in the data and they are too variable: data generation is uncontrolled (timeframe from exposure etc.) and the outcome is too experimental conditionspecific to be meaningful. Anyone can publish 'omics data, and we would have no way of verifying whether the data is accurate or not. Further, it continues to be difficult to correlate 'omics data to actual adverse effects, let alone to determine human relevance.
(3b) At this moment, 'omics might be useful to support the POD, but we are hesitant to use it as a POD for the above limitations. In general, the data should be more transparent and accessible. And if it is not already part of the ECETOC workshop
Applying 'omics in chemicals risk assessment, application of assessment factors to 'omics data should be discussed. This would be whether the full set of assessment factors are required when the start of a chemical risk assessment is based on 'omics.
Respondent D:
(1) We regularly utilise in vitro gene expression data for early internal decision making as well as in vivo to help guide our testing programmes; i.e. as supporting data for all crop protection products. In the case of industrial chemicals, it is more performed on a case-by-case basis. For crop protection products, we are doing proactive 'omics evaluation (Next Generation Sequencing (NGS), transcriptomics) as a default. As these molecules move through the pipeline, we will submit the respective data to the regulatory agencies.
(2a) There are only a few situations where we have utilised full 'omics data via microarray or NGS for a regulatory submission. These have been situations where we have wanted to dig into a very complex MoA.
(2d) In some cases, the authorities have utilised the gene expression data to help support a MoA and determine relevance, or lack thereof, to humans. In other cases, they have driven the NOAEL off of the gene expression data alone! In one case, the authority allowed us to waive the 2-year cancer bioassay based upon MoA and gene expression data.
